Ahead of the pivotal Phase III MAVERIC topline results, expected in mid-2027, Cardiol Therapeutics (TSX: CRDL) (Nasdaq: CRDL) has seen a pronounced uptick in its stock over the past couple of months. Since closing at $1.00/share on July 8, the price has increased over +65% on much higher and more consistent volume. With just a surface glance at the company, it might be easy for an investor who hasn’t followed the story to think that this run might be peaking already. But a review of the analysts covering Cardiol reveals a batch of experts who all think this is just the beginning
The Analysts
- B. Riley Financial — Analyst Mayank Mamtami — Buy Rating — $11.00 Price Target — Initiated coverage on Aug. 26, 2026
- Canaccord Genuity — Analyst Edward Nash — Buy Rating (since Dec. 2021) — $10.00 Price Target — Raised from $8.00 on Aug. 17, 2026
- H.C. Wainwright — Analyst Brandon Folkes — Buy Rating (since Jan. 2025) — $9.00 Price Target — Reiterated on July 14, 2026
- Brookline Capital — Analyst Fozia Ahmed — Buy Rating (since Sept. 2025) — $5.00 Price Target — Reiterated on Sept. 24, 2026
Wall Street’s current price targets point to upside in the 3x to 6x range, with the most recent initiation, by B. Riley, setting a 12-month timetable on its $11.00 price target. Recent guidance from the company states that topline results from its Phase III MAVERIC trial evaluating CardiolRx™ for the reduction in risk of recurrence in patients with recurrent pericarditis are anticipated in mid-2027.
In drug development, trial results are the clear catalysts; more so with Phase III results. In Cardiol’s case, a positive Phase III MAVERIC readout would alter the company’s profile almost completely. The FDA has already granted CardiolRx™ Orphan Drug Designation for its pericarditis program, and the company has consulted with the agency on trial design and endpoints to ensure both the regulator and the company are aligned on the study. Favorable results would almost certainly lead to a New Drug Application, which would be Cardiol’s first.
The B. Riley report notes that one biologic – a costly, injectable, potentially immunosuppressive therapy, has already validated and demonstrated the value of the recurrent pericarditis market: Kiniksa Pharmaceuticals’ (Nasdaq: KNSA) rilonacept (ARCALYST®), the main driver of Kiniksa’s ~$6.1 billion valuation and the only treatment currently approved by the FDA for recurrent pericarditis. This IL-1 blocker drug is projected to earn between $980 – $995 million in FY’26. The analyst believes Cardiol’s drug candidate, CardiolRx™, could offer an improvement due to fewer side effects, oral administration vs. injection, and a cost anticipated to be lower than the $300k+/year price tag for ARCALYST®.
The Institutions
It appears that institutional ownership is on the upswing as Cardiol’s pivotal MAVERIC trial results are approaching. Smaller pharma stocks often appreciate in the months leading up to a Phase III readout, and that dynamic appears to be happening currently.
According to Yahoo! Finance, as of June 30, 2026 about 25% of Cardiol shares were held by a total of 59 institutions. According to the form 13F data compiled by WhaleWisdom, 24 institutions reported owning at least 30,000 shares. In total for the quarter ended June 30, these 24 institutions added 1,991,383 shares to their holdings while selling 266,059. On balance the top holders upped their investments by 1,725,324 shares during the quarter.
The Upshot for Investors
Biopharmaceutical investing is an exercise in patience with often long waits for trial results while reading the tea leaves, or better yet, evaluating the evidence as covered by the analysts, on what might come next. Between the analyst Buy ratings with significant upside and the institutional involvement from savvy biotech pros, retail investors have a lot of positive reference points to consider when it comes to Cardiol Therapeutics. Valuation swings are typical prior to key milestones like the reporting of Phase III results, however the signs right now from the experts in the sector are pointing decidedly up.
Author’s Disclosure: This article reflects the author’s independent analysis and personal views. The content is provided for informational purposes only and should not be considered financial or investment advice. Readers are encouraged to conduct their own independent research and due diligence before making any investment decisions.
